Acadia Pharmaceuticals (ACAD) Inventory (2016 - 2026)

Acadia Pharmaceuticals has reported Inventory for 11 years, with the latest figure at $31.6 million in Q1 2026.

• For the quarter ending Q1 2026, Inventory rose 37.59% year-over-year to $31.6 million; the trailing twelve-month figure through Mar 2026 stood at $31.6 million (up 37.59% YoY), and the FY2025 full-year result was $34.7 million, up 57.96% from the prior year.
• Inventory for Q1 2026 stood at $31.6 million, down from $34.7 million in the prior quarter.
• The five-year high for Inventory was $71.5 million in Q2 2024, with the low at $5.8 million in Q3 2022.
• Average Inventory over 5 years is $27.0 million, with a median of $22.9 million recorded in 2025.
• Year-over-year, Inventory surged 916.18% in 2024 and tumbled 63.48% in 2025.
• Tracing ACAD's Inventory over 5 years: stood at $6.6 million in 2022, then surged by 439.77% to $35.8 million in 2023, then slumped by 38.72% to $21.9 million in 2024, then jumped by 57.96% to $34.7 million in 2025, then dropped by 8.93% to $31.6 million in 2026.
• The last three Inventory figures came in at $31.6 million (Q1 2026), $34.7 million (Q4 2025), and $29.1 million (Q3 2025), per Business Quant data.

Peer Comparison